Read Post Market Analysis published at 4 pm everday. click here
  1. home
  2. Company
  3. Biocon
  4. Financials

Pivot Points
08 Jul 2020 03:33 PM IST
Name S3 S2 S1 Pivot Points R1 R2 R3
Fibonacci 392.50 395.88 397.97 401.35 404.73 406.82 410.20
Bollinger band (1,2) - 392.33 393.13 393.13 393.13 393.93 -

Technical Indicator
Name Value
Adx(14) 35.35
Rsi(14) 35.35
Stoch Rsi(14) 0.00
MACD(12,26) 7.71
Williams %R -96.02
ROC -5.07
Moving Averages
Period Simple Exponential
MA 9 396.52 396.96
MA 20 393.13 391.60
MA 50 372.05 372.89
MA 100 338.33 347.76
MA 200 303.82 317.46
Related News

Trending stocks: Biocon shares trade flat in early session

update 06 Jul 10:57 AM

A total of 33,881 shares changed hands on the counter till 11:01AM (IST).

Stocks in the news: Reliance Ind, ICICI Bank, Future Retail, Indiabulls Housing, YES Bank, Biocon and NBCC

update 06 Jul 07:26 AM

Lupin, Marksans Pharma, Aurobindo Pharma and Alembic Pharmaceuticals are recalling products in the US market.

Trending stocks: Biocon shares rise nearly 1%

update 03 Jul 10:54 AM

A total of 29,814 shares changed hands on the counter till 10:56AM (IST).

Biocon lines up $200 million capex for current fiscal

update 02 Jul 06:38 PM

The company's capital expenditure during 2019-20 stood at Rs 974.2 crore, Mittal said.

Biocon lines up Rs 1,500 crore capex for the current fiscal

update 02 Jul 06:25 PM

We expect capex (capital expenditure) spends to be $200 million in 2020-21, split equally between small molecules and the biosimilars businesses, Mittal said..

Share market update: Pharma shares advance; Biocon rises 1%

update 02 Jul 11:55 AM

The Nifty Pharma index was trading 0.25 per cent up at 9907.7.

Is it a crime to do asymptomatic testing? Biocon chief expresses anguish

update 26 Jun 02:09 PM

The Executive Chairperson of Bengaluru-headquartered biotech major, Biocon Ltd, said given the size of the country, the rising number of cases is expected when the economy is opened up after COVID-19-induced lockdown.

BIOCON at 52 Week High; BSE 500 Index Up 1.0%

update 26 Jun 09:23 AM

Posted by Equitymaster BIOCON share price has hit a 52-week high at Rs 409 (up 1.0%). Meanwhile, the BSE 500 Index is at 13,610 (up 0.8%). Among the top gainers in the BSE 500 Index today are BIOCON (up 1.0%) and PNC INFRATECH (up 10.0%). MAS FINANCIAL SERVICES LTD (down 8.4%) and SOMANY CERAMICS (down 6.7%) are among the top losers today. Over the last one year, BIOCON has moved up from Rs 246 to Rs 409, registering a gain of Rs 162 (up 65.65%). The BSE 500 has moved down from 15,254 to 13,610, loss of 1,644 points (down 10.9%) during the last 12 months. The top gainers among the BSE 500 Index stocks during this same period were DIXON TECHNOLOGIES (up 158.4%), ICICI SECURITIES LTD (up 121.2%) and NAVIN FLUORINE (up 120.5%). Rapid Profits Summit: Just 2 Days Left to Book Your FREE Seat What About the Benchmark Indices? The BSE Sensex is at 35,189 (up 0.8%). The top gainers among the BSE Sensex stocks today are INDUSIND BANK (up 2.7%), ITC (up 2.4%) and INFOSYS (up 1.8%). Other gainers include ICICI BANK (up 1.7%) and BAJAJ FINSERV (up 1.4%). The most traded stocks in the BSE Sensex are ITC and SBI. In the meantime, NSE Nifty is at 10,389 (up 0.8%). INDUSIND BANK (up 3.1%) and ONGC (up 2.1%) are among the top gainers in NSE Nifty. Over the last 12 months, the BSE Sensex has moved up from 39,435 to 35,189, registering a gain of -4,246 points (up -11.0%). BIOCON Financial Update... BIOCON net profit down at Rs 2 billion for the quarter ended March 2020, compared to a loss of Rs 2 billion a year ago. Net Sales declined 9.6% to Rs 15.8 billion during the period as against Rs 17.5 billion in January-March 2019. For the year ended March 2019, BIOCON reported 132.0% increase in net profit to Rs 10.0 billion compared to net profit of Rs 4.3 billion during FY18. Revenue of the company grew 33.5% to Rs 55 billion during FY19. The current Price to earnings ratio of BIOCON , based on rolling 12 month earnings, stands at 31.1x. This article (BIOCON at 52 Week High; BSE 500 Index Up 1.0% ) is authored by Equitymaster. Equitymaster is a leading 'independent' equity research initiative focused on providing well-researched and unbiased opinions on stocks listed on the Bombay Stock Exchange.

Biocon to expand generic drugs business with DKSH

update 22 Jun 05:24 PM

As a part of the pact, DKSH will gain an exclusive license to register and commercialize these seven generic formulations from various therapeutic areas like diabetology, cardiology, oncology and immunology, which will be sold under Biocon’s brand in these key Asian markets.

D-Street Buzz: Pharma stocks rally; Glenmark zooms 35%, Cipla, Sun Pharma, Biocon gain

update 22 Jun 12:45 PM

Cipla jumped over 4 percent after the country's drug regulator on June 20 gave permission to Hetero and Cipla to manufacture and market antiviral drug remdesivir while Lupin, Sun Pharma, Torrent Pharma, Biocon and Divis Labs were the other gainers.


Open Zerodha account launch

( ₹ 20 / Trade )